0000000000015814

AUTHOR

Ingrid Ricard

showing 3 related works from this author

Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergo…

2021

Body weight loss is frequently regarded as negatively related to outcomes in patients with malignancies. This retrospective analysis of the FIRE-3 study evaluated the evolution of body weight in patients with metastatic colorectal cancer (mCRC). FIRE-3 evaluated first-line FOLFIRI (folinic acid, fluorouracil and irinotecan) plus cetuximab or bevacizumab in mCRC patients with RAS-WT tumors (ie, wild-type in KRAS and NRAS exons 2-4). The prognostic and predictive relevance of early weight loss (EWL) regarding patient outcomes and treatment side effects were evaluated. Retrospective data on body weight during first 6 months of treatment were evaluated (N = 326). To correlate with efficacy endp…

Cancer Researchmedicine.medical_specialtyBevacizumabbusiness.industryColorectal cancerHazard ratioOdds ratiomedicine.diseaseGastroenterologyIrinotecanOncologyWeight lossInternal medicineFOLFIRIMedicinemedicine.symptomRisk factorbusinessmedicine.drugInternational Journal of Cancer
researchProduct

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

2017

Abstract Background We explored the impacts of sequential application of various treatment lines on survival kinetics. Therefore, differences in overall survival (OS) observed in FIRE-3 were investigated in the context of time and exposure to applied treatment. Patients and methods OS analyses (stratified by treatment with FOLFIRI plus either cetuximab or bevacizumab) were performed according to time intervals as well as using a Cox model to define changes of hazard ratio (HR) over time. Results The fraction of patients with systemic treatment and time on treatment markedly decreases over treatment lines and time. OS evaluation by a Cox model indicated a trend towards a non-proportional haz…

OncologyCancer Researchmedicine.medical_specialtyTime FactorsBevacizumabLeucovorinCetuximabContext (language use)Angiogenesis InhibitorsKaplan-Meier Estimatemedicine.disease_causeProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumans030212 general & internal medicineNeoplasm MetastasisSurvival analysisProportional Hazards ModelsCetuximabProportional hazards modelbusiness.industryHazard ratioIntention to Treat AnalysisBevacizumabTreatment OutcomeOncology030220 oncology & carcinogenesisMutationFOLFIRICamptothecinKRASFluorouracilbusinessColorectal Neoplasmsmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Time-course evaluation of survival and treatment in FIRE-3 trial (AIO KRK0306).

2016

3528Background: To investigate overall survival (OS) differences in FIRE-3 in context of exposure to treatments (i.e. first-, second-, third-line) in time course. Methods: We compared OS in FIRE-3 ...

OncologyCancer Researchmedicine.medical_specialtynervous systemOncologybusiness.industrymusculoskeletal neural and ocular physiologyInternal medicineTime coursemedicineOverall survivalContext (language use)businessJournal of Clinical Oncology
researchProduct